U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Meropenem - Injection products
  1. Development Resources

Meropenem - Injection products

 

 

Minimum Inhibitory
Concentrations

(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacteralesa

M100 standard is recognized

Pseudomonas aeruginosa

M100 standard is recognized

Acinetobacter spp*

M100 standard is recognized

Haemophilus influenzae and parainfluenzae

M100 standard is recognized

Streptococcus pneumoniae

M100 standard is recognized

-

-

-

Streptococcus spp β- Hemolytic Group

M100 standard is recognized

-

-

-

Streptococcus spp Viridans Group

M100 standard is recognized

-

-

-

Neisseria meningitidis

M100 standard is recognized

Anaerobes

M100 standard is recognized

-

-

-

aIncluding Salmonella spp. and Shigella spp.

S = Susceptible; I = Intermediate; R = Resistant
* dosing regimen of 1 gram every 8 hours infused over 60 minutes

Exceptions to the recognized standard

For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:

Burkholderia cepacia complex

Other Non-Enterobacterales

Back to Top